Oximesa SLU

Nippon Gases, the European subsidiary of the Japanese Nippon Sanso Holdings Corporation (NSHD), Corporación Químico-Farmacéutica Esteve (CQFE) and Teijin Holdings Europe BV (Teijin) have entered into an agreement for the acquisition of Esteve Teijin Healthcare (ETH). ETH is a joint venture company set up in 2009 by Teijin and CQFE, which specialises in respiratory home therapies and aligns seamlessly with Nippon Gases’ existing business model – delivering high-quality care and innovative services. This agreement will combine ETH’s extensive knowledge in respiratory therapies with Nippon Gases’ field expertise, ensuring a stronger industry presence. In Spain, Nippon Gases offers respiratory therapy services through its subsidiary Oximesa, and together with ETH, will cover more regions with minimal overlap, with the new structure leveraging the full potential of both organisations for continued growth. Justin Corcho, CEO, Nippon Gases España, said: “This is a truly historic combination, culturally and strategically, within the Spanish Homecare market. Nippon Gases has been on a transformation journey to become Spain’s leading homecare and respiratory business, and this opportunity to welcome Esteve Teijin Healthcare (ETH) enables us to further realise our full potential and vision. We are excited to bring together both companies’ world-class talent and capabilities, and our shared commitment to providing the best patients care. With a proven track record of successfully and sustainably nurturing and growing acquired businesses, we are confident Nippon Gases is a natural home for the ETH business and employees.” Both Teijin and CQFE agree that Nippon Gases is the ideal entity to lead the respiratory home therapy market in Spain and Europe, with this strategic step ensuring the continued development of ETH’s innovative approach and marks its future sustainability. "We are convinced that this agreement will mean a great challenge for our company, representing a significant step forward in improving patient care and quality of life. Combining our expertise, successful service model and strong know-how in the market with Nippon Gases will enable us to deliver even more innovative and effective solutions in the field of home respiratory therapies” said Carlos Fina, CEO of Esteve Teijin Healthcare. Closing of the transaction remains subject to customary conditions and regulatory approvals, including one by the Spanish Comisión Nacional de los Mercados y de la Competencia. Advisors for Teijin and CQFE included KPMG and Faus Moliner. Advisors for Nippon Gases included CMS Albiñana & Suárez de Lezo and Kroll Advisory, S.L.